KDC-MN-150 – Kodiac biolabs

Plain-language summaryIntrigue 78 / 100

Suvorexant, sold as Belsomra, is a dual orexin receptor antagonist (DORA), the first of a new sleep medication class. Unlike GABAergic hypnotics it works by blocking the wakefulness-promoting orexin system. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

57/100

First-in-class DORA with a clean mechanistic story, but the novelty window has closed

Suvorexant was genuinely exciting when Merck cleared the FDA in 2014. It was the first commercialized DORA, and that represented a clean conceptual break from the GABAergic sedative tradition that had dominated sleep pharmacology for decades. Instead of dampening CNS excitability broadly, it blocks orexin-A and orexin-B at both OX1R and OX2R, removing the active drive to wakefulness rather than forcing sedation. Thats a real mechanistic contribution, and it’s still the reason the DORA class earns serious bench attention at all.

Here’s the thing though: that novelty window is essentially closed. Suvorexant has been on market twelve years. The pivotal METEOR and SORReL trials are thoroughly characterized. Lemborexant came in with a sharper half-life profile, daridorexant demonstrated competitive tolerability data in phase 3, and suvorexant is now the reference standard in a maturing class rather than the frontier of it. The 12-hour plasma half-life driven by CYP3A4 clearance creates morning residual sedation concerns that newer entrants specifically addressed. A bench scientist choosing a DORA probe today has reasons to reach past suvorexant rather than defaulting to it.

What keeps it genuinely relevant is the orexin system’s expanding research surface beyond insomnia. The glymphatic clearance hypothesis has pulled DORAs into Alzheimer’s biology in a serious way. The Ju group at Washington University published mechanistic work suggesting orexin-driven wakefulness disrupts CSF-ISF exchange responsible for amyloid and tau clearance during sleep, making suvorexant an active tool in neurodegeneration research programs rather than just a sleep drug. That hypothesis has been tested clinically (NCT03975114 examined amyloid accumulation under DORA conditions directly). The effect size and durability aren’t established, but the question is real. Similarly, orexin’s role in reward circuitry and drug-seeking behavior has made suvorexant a useful pharmacological probe in addiction neuroscience, where blocking orexin signaling attenuates cue-induced reinstatement in preclinical models.

We think the honest framing for a research library is this: suvorexant is a high-quality reference compound for orexin biology, with excellent evidence quality for its approved indication and early-but-credible signals in neurodegeneration and addiction circuits. What we don’t love is that the most compelling orexin research right now tends to treat suvorexant as a comparator or proof-of-concept tool rather than the object of study itself. If your program is centered on orexin system biology, it’s an important reagent. If you’re hunting the frontier of the sleep-cognition-longevity space, the orexin angle is genuinely interesting but suvorexant is the well-characterized older member of a class that’s rapidly gaining better-optimized successors. Schedule IV. Research-use context only.

Novelty: 35
Mechanism promise: 60
In-category differentiation: 45
Evidence quality: 75
Translational signal: 72
Research bench value: 65

Rationale Suvorexant scores well on evidence and translational signal as a phase-3-backed FDA-approved drug, but twelve years post-approval its novelty is largely spent and newer DORAs (lemborexant, daridorexant) address its PK weaknesses; what keeps the score from collapsing further is the orexin system’s emerging roles in neurodegeneration and addiction, where suvorexant still functions as the reference probe.

Dual orexin receptor antagonist

A dual orexin receptor antagonist (DORA) FDA-approved as Belsomra for insomnia, the first commercialized of the DORA class.

Abstract

Suvorexant (Belsomra; MK-4305; CAS 1030377-33-3; molecular formula C23H23ClN6O2; molecular weight 450.92) is a dual orexin receptor (OX1R, OX2R) antagonist developed by Merck and approved by the FDA in 2014 for insomnia. The compound was the first commercialized DORA. Mechanism is competitive antagonism at orexin-A (hypocretin-1) and orexin-B (hypocretin-2) binding sites on OX1R and OX2R, attenuating orexinergic wakefulness signaling without GABAergic hypnotic effects. Pharmacokinetics: plasma half-life 12 hours; CYP3A4 metabolism. Approved doses are 5 to 20 mg at bedtime. Schedule IV.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-150Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-150

Suvorexant

Abstract

Read the full monograph